Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography

ARYA Atherosclerosis

Volumn 10, Issue 5, 2014, Pages

  Sanei, Hamid ^a   Hajian Nejad, Alireza ^b   Sajjadieh Kajouei, Amirreza ^c   Nazemzadeh, Neda ^d   Alizadeh, Nehzat ^b   Bidram, Peyman ^b   Pourheidar, Behrouz ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Contrast media; Hydroxymethylglutaryl CoA reductase Inhibitors; Kidney diseases; Multidetector computed tomography

Indexed keywords

ATORVASTATIN; CREATININE; IOPROMIDE; PLACEBO;

ADULT; ARTICLE; COMORBIDITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 84907092482     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bamberg F, Marcus RP, Schlett CL, Schoepf UJ, Johnson TR, Nance JW, et al. Imaging evaluation of acute chest pain: systematic review of evidence base and cost-effectiveness. J Thorac Imaging 2012; 27(5): 289-95.
2. Nance JW, Bamberg F, Schoepf UJ. Coronary computed tomography angiography in patients with chronic chest pain: systematic review of evidence base and cost-effectiveness. J Thorac Imaging 2012; 27(5): 277-88.
3. Hopyan JJ, Gladstone DJ, Mallia G, Schiff J, Fox AJ, Symons SP, et al. Renal safety of CT angiography and perfusion imaging in the emergency evaluation of acute stroke. AJNR Am J Neuroradiol 2008; 29(10): 1826-30.
4. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51(15): 1419-28.
5. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79(2): 211-9.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105(19): 2259-64.
7. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 2010; 5(1): 4-9.
8. Lencioni R, Fattori R, Morana G, Stacul F. Contrastinduced nephropathy in patients undergoing computed tomography (CONNECT) -a clinical problem in daily practice? A multicenter observational study. Acta Radiol 2010; 51(7): 741-50.
9. Krol AL, Dzialowski I, Roy J, Puetz V, Subramaniam S, Coutts SB, et al. Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography. Stroke 2007; 38(8): 2364-6.
10. Aronow HD, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL, et al. Predictors of length of stay after coronary stenting. Am Heart J 2001; 142(5): 799-805.
11. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275(19): 1489-94.
12. Asif A, Epstein M. Prevention of radiocontrastinduced nephropathy. Am J Kidney Dis 2004; 44(1): 12-24.
13. Ide JM, Lancelot E, Pines E, Corot C. Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view. Invest Radiol 2004; 39(3): 155-70.
14. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 2004; 44(9): 1763-71.
15. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44(7): 1393-9.
16. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292(5519): 1160-4.
17. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol 2011; 153(3): 323-5.
18. Zhang L, Zhang L, Lu Y, Wu B, Zhang S, Jiang H, et al. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract 2011; 65(5): 624-30.
19. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004; 4: 26.
20. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrastinduced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105(3): 288-92.
21. Goldfarb S, McCullough PA, McDermott J, GaySB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc 2009; 84(2): 170-9.
22. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; (100): S11-S15.
23. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148(4): 284-94.
24. Kwok CS, Pang CL, Yeong JK, Loke YK. Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol 2013; 86(1021): 20120272.
25. O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology 2013; 64(8): 576-82.
26. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 2011; 33(4): 344-51.
27. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of shortterm high-dose statin in preventing contrastinduced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012; 7(4): e34450.
28. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrastinduced nephropathy. Am J Cardiol 2006; 98(6A):14K-20K.
29. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC, Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990; 258(1 Pt 2): F115-F120.
30. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21(12): 1896-901.
31. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101(12): 2711-9.
32. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J 2003; 24(3): 225-48.
33. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154(1): 87-96.
34. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91(8): 696-703.
35. Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol 2010; 33(4): 222-7.
36. Su Y, Xu Y, Sun YM, Li J, Liu XM, Li YB, et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2010; 55(1): 21-5.